8-K
filed March 30, 2026, 7:59 PM ET
ticker ARTL
CIK 0001621221
other material
confidence high
sentiment neutral
materiality 0.70
Artelo Biosciences closes $11M private placement; expects to regain Nasdaq compliance
ARTELO BIOSCIENCES, INC.
- Gross proceeds $11.0M from sale of 3.19M common shares (or pre-funded warrants) and 6.38M common warrants at $3.45/unit.
- Net proceeds of $10.03M to be used for working capital, corporate purposes, and repayment of bridge debt.
- Common warrants exercisable at $3.20 for 5.5 years; potential additional proceeds of $20.4M if fully cash-exercised.
- Proceeds push stockholders' equity above $2.5M threshold; company awaiting Nasdaq confirmation of compliance.
- H.C. Wainwright acted as placement agent, receiving 8% cash fee plus warrants for 255,073 shares at $4.3125.
Key facts
Extracted from this filing and checked against the source text.
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
ARTELO BIOSCIENCES, INC. issued pre-funded warrants to purchase 3,107,407 shares of common stock of warrant to certain accredited investors for $3.449 per Pre-Funded Warrant and two Common Warrants.
- Security
- warrant
- Shares
- pre-funded warrants to purchase 3,107,407 shares of common stock
- Purchaser
- certain accredited investors
- Consideration
- $3.449 per Pre-Funded Warrant and two Common Warrants
Exact text from the filing
On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
ARTELO BIOSCIENCES, INC. issued warrants to purchase 6,376,814 shares of common stock of warrant to certain accredited investors for Each Share or, at the election of the Purchaser in lieu of Shares, each Pre-Funded Warrant, was issued and sold along with two Common Warrants.
- Security
- warrant
- Shares
- warrants to purchase 6,376,814 shares of common stock
- Purchaser
- certain accredited investors
- Consideration
- Each Share or, at the election of the Purchaser in lieu of Shares, each Pre-Funded Warrant, was issued and sold along with two Common Warrants
Exact text from the filing
On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.99
ARTELO BIOSCIENCES, INC. issued 81,000 shares of common stock of common stock to certain accredited investors for $3.45 per share.
- Security
- common stock
- Shares
- 81,000 shares of common stock
- Purchaser
- certain accredited investors
- Consideration
- $3.45 per share
Exact text from the filing
On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors (the “Purchasers”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”): (i) 81,000 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”) at $3.45 per share, (ii) pre-funded warrants to purchase 3,107,407 shares of Common Stock at an exercise price of $0.001 per share (the “Pre-Funded Warrants”), and (iii) warrants to purchase 6,376,814 shares of Common Stock at an exercise price of $3.20 per share (the “Common Warrants”).
View on SEC.gov
Equity Issuances
SEC 8-K Item 3.02/3.03
confidence 0.9
ARTELO BIOSCIENCES, INC. issued warrants to purchase 255,073 shares of common stock of warrant to designees of the Placement Agent (H.C. Wainwright & Co., LLC) for issuance to designees of the Placement Agent.
- Security
- warrant
- Shares
- warrants to purchase 255,073 shares of common stock
- Purchaser
- designees of the Placement Agent (H.C. Wainwright & Co., LLC)
- Consideration
- issuance to designees of the Placement Agent
Exact text from the filing
In addition, the Company issued to designees of the Placement Agent warrants to purchase 255,073 shares of Common Stock at an exercise price of $4.3125 per share (the “Placement Agent Warrants”), which have the same terms as the Common Warrants other than the exercise price.
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.95
ARTELO BIOSCIENCES, INC. entered into Purchase Agreement with certain accredited investors valued at $10,996,902.70 (effective 2026-03-27).
- Action
- entry
- Agreement
- equity purchase
- Counterparty
- certain accredited investors
- Value
- $10,996,902.70
- Effective
- 2026-03-27
Exact text from the filing
On March 27, 2026, Artelo Biosciences, Inc. (the “Company”) entered into a securities purchase agreement (the “Purchase Agreement”) with certain accredited investors
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.